Background Severe coronavirus disease 2019 (COVID‐19) is characterized by a
proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may …

Aim Patients with type 2 diabetes mellitus (T2DM) represent a high-risk population for both
cardiovascular diseases and severe coronavirus disease 2019 (COVID-19). Recent studies …

Background Statins have anti-inflammatory and immunomodulatory effects that may reduce
the severity of coronavirus disease 2019 (COVID-19), in which organ dysfunction is …

Aims People with cardiovascular disease or risk factors are at increased risk when exposed
to SARS-CoV-2. Most are treated with statins, but the impact of these drugs on clinical …

Abstract The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state,
leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic …

Background There is an urgent need for novel therapeutic strategies for reversing COVID-19-
related lung inflammation. Recent evidence has demonstrated that the cholesterol-lowering …

Background and aims The coronavirus disease 2019 (COVID-19) number of death cases is
still increasing. One of the comorbidities associated with severe outcome and mortality of …

We aim to study the association of hyperlipidemia and statin use with COVID-19 severity. We
analysed a retrospective cohort of 717 patients admitted to a tertiary centre in Singapore for …

Background Coronavirus disease 2019 (COVID-19) might affect everyone, but people with
comorbidities such as hypertension and cardiovascular disease (CVD) may often have more …

The coronavirus disease-2019 (COVID-19) is caused by SARS-CoV-2, leading to acute
respiratory distress syndrome (ARDS), thrombotic complications, and myocardial injury …